New Developments in Non-allergen-specific Therapy for the Treatment of Food Allergy
Purpose of Review
The prevalence of food allergy is increasing. At the current time, there are no approved treatments for food allergy. Major limitations of immunotherapy are long treatment periods (months or years), frequent clinic visits, high costs, increased risk of adverse events during treatment, and lack of durability of desensitization. Additionally, it is allergen-specific, and in those allergic to multiple allergens, the length and cost of treatment are further increased. In this review, we summarize recent developments in novel non-allergen-specific treatments for food allergy.
A number of monoclonal antibodies that block IgE or specific pro-allergenic cytokines or their receptors have shown promise in clinical trials for food allergy.
The insight we have gained through the use of one drug for the treatment of an atopic disease is quickly being translated to other atopic diseases, including food allergy. The future for food allergy treatment with biologics looks bright.
KeywordsFood allergy Immunotherapy Biologics Atopy Omalizumab Dupilumab
We thank Dr. Kari Nadeau for her critical review of the paper.
AJL, MB, and VS performed the literature search and drafted and critically revised the work. RSC drafted and critically reviewed the work.
This work was financially supported by the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.
Compliance with Ethical Standards
Conflict of Interest
Dr. Sharon Chinthrajah receives grant support from CoFAR NIAID, Aimmune, DBV Technologies, Astellas, AnaptysBio, Novartis, and Regeneron and is a scientific advisory board member for Alladapt Immunotherapeutics. All other authors declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 1.Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics. 2018;142.Google Scholar
- 14.Fleischer DM, Greenhawt M, Sussman G, Begin P, Nowak-Wegrzyn A, Petroni D, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial. JAMA. 2019;321:946–55.PubMedPubMedCentralCrossRefGoogle Scholar
- 27.•• Chinthrajah RS, Purington N, Andorf S, Long A, O’Laughlin KL, Lyu SC, et al. Sustained outcomes in a large double-1 blind, placebo-controlled, randomized phase 2 study of peanut immunotherapy. Lancet. Accepted June 14,2019 In Press. 2019. OIT could desensitize individuals with peanut allergy to 4000 mg peanut protein but discontinuation, or even reduction to 300 mg daily, could increase the likelihood of regaining clinical reactivity to peanut.Google Scholar
- 32.Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019.Google Scholar
- 60.•• Andorf S, Purington N, Kumar D, Long A, O’Laughlin KL, Sicherer S, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. EClinicalMedicine. 2019;7:27–38. Omalizumb with oral immuotherapy shows promise and decreases time to desensitization and simultaneously desensitizes to multiple allergens. PubMedPubMedCentralCrossRefGoogle Scholar
- 69.•• Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137:1103–10 e11. Measurements of safety significantly improved with adjunctive omalizumab in combination with food oral immunotherapy. PubMedGoogle Scholar
- 73.•• Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3:85–94. In patients with allergies to multiple foods, omalizumab improves the efficacy of multifood oral immunotherapy and enables safe and rapid desensitisation. CrossRefGoogle Scholar
- 75.Patil SP, Wang J, Song Y, Noone S, Yang N, Wallenstein S, et al. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: extended phase I study. J Allergy Clin Immunol. 2011;128:1259–65 e2.PubMedPubMedCentralCrossRefGoogle Scholar
- 77.•• Frischmeyer-Guerrerio PA, Masilamani M, Gu W, Brittain E, Wood R, Kim J, et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2017;140:1043–53 e8. Baseline biomarkers (alterations in basophil reactivity) can identify subjects most likely to benefit from adjunctive therapy with omalizumab. Google Scholar
- 83.Dupilumab (Dupixent) for asthma. JAMA. 2019;321:1000–1.Google Scholar
- 91.Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–27.PubMedCrossRefGoogle Scholar
- 95.Cherie Liu SC, Long A, Lyu S-C, Londei M, Nadeau KC. Randomized controlled phase 2a study results using anti IL-33 in food allergy. J Immunol. 2019;202(1 Supplement):196.1.Google Scholar